Kenvue Appoints Kirk Perry As Interim CEO After Thibaut Mongon Departs

Kenvue (KVUE) has appointed Kirk Perry as Interim CEO, replacing Thibaut Mongon, effective immediately, as its Board initiates a comprehensive review of strategic alternatives aimed at unlocking shareholder value and accelerating profitable growth. Concurrently, the consumer health company reported preliminary second-quarter results significantly below analyst expectations, projecting EPS of $0.21-$0.22 (adjusted $0.28-$0.29) and a 4% net sales decline, sharply contrasting with analyst consensus for $0.32 EPS and 3.38% revenue growth.

Analysis

Kenvue Inc. is undergoing a significant operational and strategic overhaul, marked by the immediate departure of its CEO and the simultaneous release of deeply disappointing preliminary second-quarter financial results. The company anticipates a 4% net sales decline and a 4.2% organic net sales decline, a stark reversal from the 3.38% revenue growth consensus forecast. Similarly, projected adjusted earnings per share of $0.28 to $0.29 fall materially short of the $0.32 analysts expected. This severe underperformance provides critical context for the board's decision to replace the CEO and launch a comprehensive review of strategic alternatives, signaling profound dissatisfaction with the current trajectory. The appointment of Kirk Perry, a seasoned consumer products executive, as interim CEO is intended to stabilize operations and guide the company through this transition. The establishment of a formal Strategic Review Committee indicates that all options, potentially including asset sales or a corporate sale, are being considered to address the performance issues and unlock shareholder value.

Key Decisions for Investors

• Investors should anticipate significant near-term share price volatility and downward pressure due to the dual negative catalysts of a severe guidance miss and abrupt CEO departure.
• The explicit review of 'strategic alternatives' creates an event-driven scenario; monitor for announcements from the new committee, as actions like divestitures or a sale could unlock value but also introduce uncertainty.
• Focus on future commentary from interim CEO Kirk Perry for any revised full-year outlook and his specific plans to reverse the material 4.2% organic sales decline, as this will be critical for re-basing valuation assumptions.